Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

@article{Eijkelkamp2007AlbuminuriaIA,
  title={Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.},
  author={Wouter B A Eijkelkamp and Zhongxin Zhang and Giuseppe Remuzzi and H H Parving and Mark Emmanuel Cooper and William F. Keane and Shahnaz Shahinfar and Gilbert W. Gleim and Matthew R. Weir and Barry M. Brenner and Dick de Zeeuw},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2007},
  volume={18 5},
  pages={1540-6}
}
Albuminuria reduction could be renoprotective in hypertensive patients with diabetic nephropathy. However, the current use of renin-angiotensin-system intervention is targeted to BP only. Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Investigated were the extent of discordance in treatment effects… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Therefore , this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo - controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) study .
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) trial .
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) trial .
Therefore , this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo - controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) study .
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) trial .
Therefore , this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo - controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) study .
Therefore , this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo - controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan ( RENAAL ) study .
All Topics